# Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

> **NCT07268222** · PHASE4 · RECRUITING · sponsor: **Laikο General Hospital, Athens** · enrollment: 150 (estimated)

## Conditions studied

- Mild Autonomous Cortisol Secretion (MACS)

## Interventions

- **DRUG:** Metyrapone 250 mg Oral Tablets
- **DRUG:** Osilodrostat 1 MG
- **PROCEDURE:** adrenalectomy
- **OTHER:** Watch and wait

## Key facts

- **NCT ID:** NCT07268222
- **Lead sponsor:** Laikο General Hospital, Athens
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-11-25
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268222, "Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07268222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*